Neuradiab + temozolomide

Neuradiab + temozolomide is a combination regimen used in the adjuvant treatment of glioblastoma multiforme (GBM). Neuradiab is a radiolabeled monoclonal antibody (anti-tenascin-C, murine 81C6) conjugated to iodine-131, locally administered into the surgical resection cavity after removal of GBM. It delivers targeted radioactivity to residual tumor cells by binding tenascin-C, which is overexpressed in GBM and absent in normal brain cells. Temozolomide is an oral alkylating agent administered systemically as a standard chemotherapeutic component of GBM treatment. The combination is designed to maximize killing of residual tumor cells through a dual modality: local radioimmunotherapy from Neuradiab targeting tenascin-C and systemic chemotherapy from temozolomide. The combination has been studied, primarily in newly diagnosed GBM, with Neuradiab provided as an adjuvant to surgery, external beam radiation, and temozolomide. Development was mainly by Bradmer Pharmaceuticals and Duke University, with Phase 3 trials conducted but ultimately terminated[1][2][3][6].

Other names

131I anti-tenascin monoclonal antibody 81c6 + temozolomide